Investor Relations Investor Center Stock Information Financial Information Corporate Governance Press Releases Events & Presentations Investor FAQ Contact Us
Press Releases Year: - Any -202420232022202120202019201820172016201520142013201220112010200920082007 Summary ToggleTekmira Pharmaceuticals Conference Call Advisory Second Quarter 2010 Operating Results and Corporate Update Aug 10, 2010 ... Read more Summary ToggleTekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP Aug 05, 2010 Tekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP 18 KB Clinical Trial for RNAi Cancer Program on Track to Commence in Second Half of 2010 ... Read more Summary ToggleTekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus Jul 15, 2010 Tekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus 20.3 KB ... Read more Summary ToggleTekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 Jul 07, 2010 Tekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 19.9 KB -ALN-TTR01 Utilizes Tekmira’s Leading SNALP Delivery Technology- ... Read more Summary ToggleTekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting Jun 07, 2010 Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting 18.8 KB ... Read more Summary ToggleTekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi May 28, 2010 Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi 22.2 KB <ul><li>Data Reflects High Potency and Utility of RNAi in Infectious Disease Applications</li></ul> ... Read more Summary ToggleTekmira Pharmaceuticals Announces First Quarter 2010 Financial Results May 13, 2010 Tekmira Pharmaceuticals Announces First Quarter 2010 Financial Results 30.2 KB ... Read more Summary ToggleTekmira Pharmaceuticals Outlines Plans for a NASDAQ Listing May 12, 2010 Tekmira Pharmaceuticals Outlines Plans for a NASDAQ Listing 17.7 KB ... Read more Summary ToggleTekmira Pharmaceuticals Conference Call Advisory - First Quarter 2010 Operating Results and Corporate Update May 11, 2010 Tekmira Pharmaceuticals Conference Call Advisory - First Quarter 2010 Operating Results and Corporate Update 12.9 KB ... Read more Summary ToggleTekmira Pharmaceuticals Announces Multi-Year Agreement with Bristol-Myers Squibb May 10, 2010 Tekmira Pharmaceuticals Announces Multi-Year Agreement with Bristol-Myers Squibb 17.9 KB Transaction includes US$3.0 million upfront payment to Tekmira ... Read more Pagination First page First Previous page Previous … Page 45 Current page 46 Page 47 Page 48 … Next page Next Last page Last Shareholder Tools Email Alerts Email Alerts RSS News Feeds RSS News Feeds Download Library Download Library
Press Releases Year: - Any -202420232022202120202019201820172016201520142013201220112010200920082007 Summary ToggleTekmira Pharmaceuticals Conference Call Advisory Second Quarter 2010 Operating Results and Corporate Update Aug 10, 2010 ... Read more Summary ToggleTekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP Aug 05, 2010 Tekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP 18 KB Clinical Trial for RNAi Cancer Program on Track to Commence in Second Half of 2010 ... Read more Summary ToggleTekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus Jul 15, 2010 Tekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus 20.3 KB ... Read more Summary ToggleTekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 Jul 07, 2010 Tekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 19.9 KB -ALN-TTR01 Utilizes Tekmira’s Leading SNALP Delivery Technology- ... Read more Summary ToggleTekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting Jun 07, 2010 Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting 18.8 KB ... Read more Summary ToggleTekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi May 28, 2010 Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi 22.2 KB <ul><li>Data Reflects High Potency and Utility of RNAi in Infectious Disease Applications</li></ul> ... Read more Summary ToggleTekmira Pharmaceuticals Announces First Quarter 2010 Financial Results May 13, 2010 Tekmira Pharmaceuticals Announces First Quarter 2010 Financial Results 30.2 KB ... Read more Summary ToggleTekmira Pharmaceuticals Outlines Plans for a NASDAQ Listing May 12, 2010 Tekmira Pharmaceuticals Outlines Plans for a NASDAQ Listing 17.7 KB ... Read more Summary ToggleTekmira Pharmaceuticals Conference Call Advisory - First Quarter 2010 Operating Results and Corporate Update May 11, 2010 Tekmira Pharmaceuticals Conference Call Advisory - First Quarter 2010 Operating Results and Corporate Update 12.9 KB ... Read more Summary ToggleTekmira Pharmaceuticals Announces Multi-Year Agreement with Bristol-Myers Squibb May 10, 2010 Tekmira Pharmaceuticals Announces Multi-Year Agreement with Bristol-Myers Squibb 17.9 KB Transaction includes US$3.0 million upfront payment to Tekmira ... Read more Pagination First page First Previous page Previous … Page 45 Current page 46 Page 47 Page 48 … Next page Next Last page Last
Tekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus 20.3 KB
Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting 18.8 KB
Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi 22.2 KB
Tekmira Pharmaceuticals Conference Call Advisory - First Quarter 2010 Operating Results and Corporate Update 12.9 KB
